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Heparin-Binding Growth Factors Based on 
CVD Polymerization 
 Xiaopei  Deng ,  Joerg  Lahann *  A multifunctional copolymer with both aldehyde and alkyne groups is synthesized by 
chemical vapor deposition (CVD) for orthogonal co-immobilization of biomolecules. Surface 
analytical methods including FTIR and XPS are used to confi rm the surface modifi cation. 
Heparin-binding growth factors [basic fi broblast growth factor (bFGF) in this study] can be 
immobilized through interaction with heparin, which was covalently attached to the CVD 
surface through an aldehyde-
hydrazide reaction. In parallel, 
an alkyne–azide reaction is 
used to orthogonally co-immo-
bilize an adhesion peptide as 
the second biomolecule.   1. Introduction 
 Precise surface engineering is one of the major challenges 
in biotechnology. [ 1 ] While it is widely recognized that the 
fate of cells cultured in vitro is determined by their local 
microenvironment consisting of both soluble and solid 
components, many biological studies focus mainly on the 
role of soluble factors, which can be controlled by simple 
methods. [ 2 , 3 ] However, the defi ned presentation of bio-
molecules on the cell culture substrates can contribute in 
equal ways to a specifi c cellular response. [ 1 , 4 ] For example, 
extracellular matrix proteins, such as fi bronectin, laminin, 
or collagen, are routinely attached to cell culture dishes to 
facilitate cell adhesion. [ 5 , 6 ] While there exists a multitude 
of immobilization methods for single biomolecules, [ 7 ] these wileyonlin
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© 2012  WILEY-VCH Verlag GmbH &  Co.  KGaA, Weinheimapproaches typically do not account for the multivalency 
of biological interactions. Controlled co-immobilization of 
multiple biomolecules is an essential requisite for certain 
biomedical applications, such as in vitro cell culture or bio-
sensors. [ 8–10 ] If proteins are immobilized through simple 
physisorption, the outcomes are governed by complex 
adsorption/desorption equilibria. [ 1 ] If multiple proteins 
are presented on a surface, the physisorption dynamics 
are governed by the Vroman effect leading to a contin-
uous exchange of proteins until coverage with the largest 
protein is obtained. [ 11 ] Thus, physisorption methods are 
unable to precisely engineer stable protein compositions 
on a surface. Alternatively, chemical immobilization can be 
employed. Simultaneous presentation of multiple biomol-
ecules to a substrate with a single surface chemistry (e.g., 
via active esters) has been previously reported. [ 8 , 9 ] How-
ever, this method is still not precise, as the cross-reactivity 
of the biomolecules may be associated with a range of 
different complications. For example, the solution compo-
sition of the biomolecules is not necessarily the fi nal com-
position encountered on the surface after immobilization. 
 A more appropriate approach is the use of orthogonal 
immobilization strategies, where a substrate presents 
multiple types of functional groups without cross-reac-
tivity. [ 12–14 ] Recently, we have established an orthogonal 
co-immobilization method for the cyclic RGD (cRGD) 
adhesion peptide and the epidermal growth factor elibrary.com 1459 DOI: 10.1002/marc.201200343 





 Scheme  1 .  a) CVD copolymerization of [2.2]paracyclophanes with aldehyde and alkyne groups.  m  =  n for the copolymer  3 discussed in this 
paper. Polymer  1 and  2 are used as controls. b) Co-immobilization scheme for heparin-binding growth factor and adhesion peptide on the 
copolymer  3 . (EGF), which uses chemical vapor deposition (CVD) co-
polymerization of two different functionalized [2.2]paracy-
clophanes yielding a polymer surface that presented acet-
ylene and pentafl uorophenol ester groups in an equimolar 
ratio. [ 13 ] In this case, coupling of the peptide was achieved 
via copper-catalyzed heterocycloaddition and the growth 
factor was linked through primary amino groups via pen-
tafl uorophenol ester groups. In our previous studies, we 
found that the choice of pentafl uorophenol ester groups 
is lacking specifi city towards the growth factor because of 
the abundance of amino groups in biomolecules. We also 
found that the immobilization of proteins through poten-
tially vital amino acids can potentially reduce their bio-
activity. [ 15 ] Whether or not the direct immobilization via 
primary amino groups is applicable will thus need to be 
validated on a case-by-case basis for each different growth 
factor. In addition, the direct immobilization approach 
does not refl ect the fact that growth factors immobilized 
on abiotic surfaces can easily undergo denaturation and 
that the use of appropriate linkers may effectively stabi-
lize the immobilized growth factors. 
 In this paper, we develop a generic immobilization 
approach for heparin-binding growth factors, which 
includes numerous commonly used growth factors, such 
as fi broblast growth factors (FGFs), vascular endothelial 
growth factor, heparin-binding EGF-like growth factor (HB-
EGF), platelet-derived growth factor, or hepatocyte growth 
factor (HGF). As an example, we selected the basic fi brob-
last growth factor (bFGF) as a model of a heparin-binding 
growth factor. However, we note that the herein developed 
procedure is equally applicable to other heparin-binding 
growth factors. It has been previously reported that binding 
to heparin protects FGF from denaturation at variant pH, at Macromol. Rapid Comm
© 2012  WILEY-VCH Verlag Ghigh temperatures, and proteolysis. [ 16–18 ] Moreover, binding 
either to heparin or heparan sulfate is a prerequisite for 
the binding of FGF to its high-affi nity receptor on the cell 
surface. [ 19 ] Considering the importance of heparin for pro-
tecting bFGF and enhancing its bioactivity, we designed 
a method to fi rst immobilize heparin on the surface and 
then tether the growth factor through the heparin-binding 
domain and charge interactions. [ 20 ] We further demonstrate 
the compatibility of this approach with the co-immobiliza-
tion of an additional biological moiety via the well estab-
lished and widely employed copper-catalyzed heterocycla-
ddition. [ 13 , 21 ] However, the CVD coatings may carry a wide 
range of different functional groups including anhydrides, 
active esters, aldehydes, ketones, amines, alkyne, as well as 
photo-reactive benzoyl groups. [ 22 ] 
 2. Experimental Section 
 2.1. Materials 
 All materials were purchased from Sigma–Aldrich and used 
without further purifi cation unless otherwise indicated. 
 2.2. CVD Co-Polymerization 
 The synthesis of the two CVD precursors used in this study, 
4-formyl[2.2]paracyclophane and 4-ethynyl[2.2]paracyclophane 
was described elsewhere. [ 22 , 23 ] As shown in Scheme  1 a, CVD 
co-polymerization was performed using 1:1 molar mixtures of 
the two precursors. The precursors sublimated under 0.07 Torr 
at temperatures above 100  ° C and were transferred in a stream 
of argon carrier gas (20 sccm) to the pyrolysis zone (670  ° C). 
Following pyrolysis, the diradicals were transferred into the  
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120  ° C and rotating sample holder cooled to 15  ° C to optimize the 
deposition. The coatings were controlled at 80–100 nm. 
 2.3. Surface Characterization 
 FTIR analysis of the coatings was carried out on a Nicolet 6700 
spectrometer with the MCT-A detector and the grazing angle acces-
sory (Smart SAGA) at a grazing angle of 80 ° . XPS was performed on 
an axis ultra X-ray photoelectron spectrometer (Kratos Analyti-
cals, UK) equipped with a monochromatized Al-K  α  X-ray source. 
All spectra were calibrated with respect to the non-functionalized 
aliphatic carbon with a binding energy of 285.0 eV. An imaging 
spectroscopic ellipsometer (Accurion, Nanofi lm EP 3 -SE, Germany) 
was used to measure fi lm thickness. Ellipsometric parameters 
were fi tted using a Cauchy model. [ 24 ] The imaging lateral resolu-
tion is  ≈ 2  μ m for the 10 × objective. Time-of-fl ight secondary ion 
mass spectrometry (TOF-SIMS) was performed on a PHI TRIFT 
V nanoTOF instrument (Physical Electronics, USA). The analysis 
conditions are the following: primary ion 30 kV Au  +  , DC current 
2.5 nA, mass range 0–1850  m / z , analysis area 400  μ m  × 400  μ m 
(256  × 256 pixels), charge compensation 15 eV e-, post acceleration 
5 kV, acquisition time 10 min ( < 1  × 10 11 ions cm  − 2 ) per data set. Data 
was collected in both ion polarities in an automated fashion using 
AutoTool. The diagnostic mass peaks were observed  < 300  m / z . 
 2.4. Immobilization of Biomolecules 
 The details and sequence for co-immobilization of the adhesion 
peptide and the heparin-binding growth factor are shown in 
Scheme  1 b. Microcontact printing ( μ CP) with PDMS stamps (prep-
aration process reported elsewhere [ 22 ] ) was used for elucidating 
the surface chemistries and creating internal reference areas that 
can be directly observed by microscopy. The method for adhesion 
peptide immobilization followed a literature-known procedure. [ 13 ] 
Briefl y, cRGD peptide with an azide end group [cyclo(azidoK-RGDf), 
Kinexus, Canada] was dissolved in an aqueous solution of sodium 
ascorbate (50 mg mL  − 1 ) and copper(II) sulfate (0.1  × 10  − 3 M ). The pep-
tide solution (50  μ g mL  − 1 ) was in contact with the CVD copolymer 
coating (polymer  3 ) for 4 h followed by thorough washing. For  Figure  1 .  FTIR spectra for polymers  1 ,  2 , and  3 . the heparin immobilization, the periodated 
heparin (Celsus Laboratories, Inc.) with alde-
hyde functional groups was used. A bivalent 
carbohydrazide linker was used to link the 
aldehyde groups on the polymer surface and 
heparin. The PDMS stamps inked with carbo-
hydrazide solution (10  μ g mL  − 1 ) were kept in 
contact with the coating surface for 20 min. 
After stamp removal, the patterned samples 
were thoroughly washed with distilled water 
and incubated in the periodated heparin solu-
tion (10 mg mL  − 1 , pH 5) overnight. To confi rm 
the success of the heparin immobilization, 
immunostaining was performed with the 
heparin antibody (anti-heparin/Heparan 
Sulfate, clone T320.11, Isotype: mouse IgG1, 
Millipore) and the Alexa Fluor® 555 anti-
mouse IgG1 (Life Technologies Corporation).  
www.MaterialsViews.com
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solution (5  μ g mL  − 1 solution in PBS with 0.1% (w/v) bovine albumin 
(BSA) and 0.02% (v/v) Tween 20 for 1 h. After washing thoroughly, 
the surface was incubated in a PBS/BSA/Tween buffer containing 
Alexa Fluor® 555 anti-mouse IgG1 (10  μ g mL  − 1 ) for 1 h. The stained 
samples were then washed with PBS, rinsed with distilled water, 
and visualized using fl uorescence microscopy (Olympus BX-51, 
Japan). For immobilization of the human bFGF (Sigma–Aldrich) 
on heparin, a heparin-presenting surface (without antibody) 
was incubated in the PBS/BSA/Tween buffer containing bFGF 
(5  μ g mL  − 1 ) for 1 h and washed thoroughly. To confi rm the suc-
cess of the bFGF immobilization, immunostaining was performed, 
as described for heparin. The only difference was that instead of 
using heparin antibody, we used an anti-human bFGF (Isotype: 
mouse IgG1, BioLegend) as the primary antibody. Other conditions 
(buffer, concentration, incubation time, secondary antibody, and 
washing procedure) were identical. 
 3. Results and Discussion 
 A novel polymer coating with orthogonal functional 
groups, poly[4-formyl- p -xylylene- co -4-ethynyl- p -xylylene-
 co - p -xylylene] (polymer  3 ), was synthesized by CVD co-
polymerization as shown in Scheme  1 a. The precursors 
4-ethynyl[2,2]paracyclophane and 4-formyl[2,2]paracy-
clophane were sublimated with a controlled feed ratio 
( m : n ,  m  =  n in this study). The mixture was then trans-
ferred through the pyrolysis zone (670 °C, 0.07 Torr) with 
help of an argon carrier gas. Free radicals were generated 
by pyrolysis and subsequently deposited and polymerized 
on the cooled substrate (15 °C, 0.07 Torr). Under these reac-
tion conditions, CVD co-polymerization yielded polymer  3 
as shown in Scheme  1 . Polymers  1 and  2 , which are shown 
for comparison, denote polymers generated using only 
one precursor and thus featuring only one reactive func-
tional group (alkyne for  1 ; aldehyde for  2 ).  1 ,  2 , and  3 were 
characterized by Fourier transform infrared (FTIR) spec-
troscopy (Figure  1 ) and X-ray photoelectron spectroscopy 1461
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 Table  1.  Chemical composition of polymers  1 ,  2 , and  3 in at% shown as experimental values determined by XPS. Theoretically calculated 
compositions are included for comparison. 
 C—C/H C—C=O C=O  π → π ∗ O
B.E.[eV] 285.0 285.7  ± 0.1 287.7  ± 0.1 291.3  ± 0.1 532 a) 
1 94.7 (100.0) – (–) – (–) 4.0 (–) 1.3 (–)
2 75.7 (83.2) 6.7 (5.6) 5.8 (5.6) 4.3 (–) 7.5 (5.6)
3 85.6 (91.6) 3.5 (2.8) 3.1 (2.8) 4.0 (–) 3.8 (2.8)
 a) Experimental values of oxygen ratio[%] are from survey results; Other experimental values for different carbon atoms with different 
chemical states are from high resolution C1s spectra. (XPS) (Table  1 ). It is clearly shown from the FTIR spectra 
that  3 has both alkyne (3285, 2100 cm  − 1 ) and aldehyde 
(1687 cm  − 1 ) functional groups, while  1 or  2 displays only 
one type of functional groups. XPS was used to further con-
fi rm the surface composition of the fi lms within the outer-
most 10 nm. [ 25 ] The percentage of total carbon and oxygen 
was obtained from the XPS survey results. High resolu-
tion peak fi tting of the C1s signal was used to determine 
the ratios of different carbon atoms at different chemical 
states. The position for C—C/H was set to be 285.0 eV for 
binding energy calibration. Other carbon atoms with dif-
ferent chemical states have different binding energies as 
shown in Table  1 . The quantitative XPS experimental data 
were in good agreement with the theoretical values calcu-
lated according to the chemical structures of the starting 
materials (Scheme  1 a). 
 After confi rming the successful preparation of the 
multifunctional reactive coating, each step for the bio-
molecules immobilization had to be validated. The overall 
design for our co-immobilization process is shown in 
Scheme  1 . Heparin was immobilized on the copolymer 
surface through the hydrazide–aldehyde reaction, which 
is highly effi cient, commonly used for bioconjugation 
and classifi ed as one of the bioorthogonal reactions. [ 14 ]  Figure  2 .  a) TOF-SIMS images of carbohydrazide patterned on polym
denoted by squares of different colors. b) Imaging ellipsometry thi
between the marked area 1 and 2 is 0.3 nm. c) Imaging XPS N1s ele
represent 50  μ m. 
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was used to link the aldehyde group of heparin and the 
aldehyde group on the copolymer  3 surface. To confi rm 
that the carbohydrazide is indeed attached to the sur-
face through covalent reaction, we conducted a ToF-SIMS 
study. ToF-SIMS is a surface-sensitive analytical tool that 
provides information on the uppermost few molecular 
layers. ToF-SIMS has been previously used in materials 
science, [ 26 , 27 ] semiconductor industry, [ 28 , 29 ] geology, [ 30 ] 
archaeometry, [ 31 ] cosmochemistry, [ 32 ] and biology. [ 33 , 34 ] 
The mass imaging capability of ToF-SIMS combines the 
potential benefi ts of chemical imaging and mass spec-
troscopy. [ 35 ] Sample surfaces in this study were coated 
with the copolymer  3 and then modifi ed by microcontact 
printing of the carbohydrazide linker. The resultant pat-
terns were clearly observable in the ToF-SIMS images. For 
all the images shown in Figure  2 a, the brighter areas were 
patterned with carbohydrazide, while the darker areas 
were not (with only the copolymer  3 coating). Signals at 
 m/z 26 and 42, which corresponded to CN  −  and CNO  −  sig-
nals were predominantly observed within the area pat-
terned with carbohydrazide. Since the polymer itself does 
not have any nitrogen, the nitrogen-containing mass 
peaks can be exclusively attributed to the presence of the  
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 Figure  3 .  Scheme and fl uorescence microscope images (a & b) after immunostaining the heparin and bFGF immobilized surface, respec-
tively. In the scheme for this Figure, we use pink to represent heparin and green to represent bFGF, the same colors used in Scheme  1 b. 
a) Fluorescence micrograph after immunostaining the immobilized heparin on the patterned carbohydrazide. b) Fluorescence micrograph 
after immunostaining the immobilized bFGF on the heparin. Scale bars are 500  μ m. carbohydrazide. Similarly, mass peaks of  m/z 59 and 89, 
which are characteristic fragments of the carbohydrazide 
linker, are signifi cantly enhanced in the surface-modi-
fi ed areas. Moreover, the mass fragment  m/z 131, which 
coincides with the  m/z 59 signal further supports the 
formation of a covalent bond between the linker and the 
polymer, albeit with lower contrast. Imaging ellipsometer 
was also used to investigate thickness variations after 
carbohydrazide patterning (Figure  2 b). The fi lm thick-
ness of the carbohydrazide immobilized onto copolymer 
 3 was measured to be 0.3 nm. For comparison, microcon-
tact printing of carbohydrazide onto polymer  1 was used 
as a control experiment, which showed no patterns based 
on imaging ellipsometry (data not shown). This contrast 
clearly demonstrates the orthogonality of the surface 
chemistries (i.e., alkyne–azide reaction versus aldehyde–
hydrazide reaction). Moreover, XPS mapping of the ele-
ment nitrogen (Figure  2 c), which was used as a reporter 
for the carbohydrazide linker, further confi rmed the ToF-
SIMS results. A cross pattern is shown in Figure  2 c. The 
relatively low signal-to-noise ratio in the XPS mapping 
experiment can be attributed to the overall low content 
of nitrogen on the surface (less than 3%). Still, taken 
together, the images shown in Figure  2 confi rm that the 
carbohydrazide was covalently attached to the copolymer 
 3 through the aldehyde–hydrazide reaction. 
 A surface displaying carbohydrazide patterns was incu-
bated in periodated heparin (with aldehyde groups) solu-
tion overnight followed by thorough rinsing with distilled 
water. After this heparin immobilization step, a heparin 
antibody and a dye-conjugated secondary antibody were 
used for immunostaining (Figure  3 , top scheme). From the 
image shown on the top right of Figure  3 , it is evident that 
heparin was immobilized only at the surface areas that 
presented carbohydrazide. Two control experiments were 
performed. For the fi rst one, we used a carbohydrazide  
www.MaterialsViews.com
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step) for the immunostaining. For the second control 
experiment, the heparin-presenting surface was in con-
tact with the secondary antibody only, but not the pri-
mary antibody (anti-heparin). Both control experiments 
did not show fl uorescence contrast for the patterns (data 
not shown). 
 After validating the heparin immobilization approach, 
the heparin-presenting surface was incubated in a bFGF 
solution (Figure  3 , bottom scheme), followed by washing 
and bFGF immunostaining. The bottom right fl uores-
cence micrograph in Figure  3 shows that bFGF was only 
immobilized at the area that presented heparin. Again, 
we included two control experiments to validate the bFGF 
immunostaining. First, the surface was patterned with 
carbohydrazide (no heparin immobilization), followed by 
the same bFGF incubation and immunostaining shown as 
in the bottom scheme of Figure  3 . Second, we performed 
every immobilization step for carbohydrazide, heparin 
and bFGF, but omitted the primary antibody. With other 
words, the resultant surface was only in contact with 
the secondary antibody. Both control experiments did 
not show fl uorescence contrast for the patterns (data not 
shown). For the heparin and the bFGF immunostaining, 
we used different primary antibody (heparin antibody 
and bFGF antibody, respectively). Because both antibodies 
belong to the isotype mouse IgG1 family, we were able 
to image both with the same secondary antibody (Alexa 
Fluor® 555 anti-mouse IgG1), hence the identical colors in 
Figure  3 . Nevertheless, a clear contrast is observed in both 
cases confi rming the selectivity of both reactions. At this 
point, we have established the success of each immobili-
zation step towards tethering the heparin-binding growth 
factor. We fi nally wanted to establish co-immobilization 
with a second biomolecule, specifi cally cRGD, via azide–
acetylene coupling. 1463
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 Figure  4 .  Imaging ellipsometry thickness map (on the right side) of a cRGD azide pattern created by  μ CP. The thickness difference between 
the marked area 1 and 2 is 0.5 nm. Scale bar represents 100  μ m.  The results for patterning an azide-functionalized cRGD 
peptide onto polymer  3 are shown in Figure  4 . Imaging 
ellipsometry was used to generate the thickness map for 
the patterned adhesion peptide on the newly synthesized 
copolymer  3 (Figure  4 ). The immobilized peptide layer 
was measured to be 0.5 nm. A control experiment with 
the same peptide patterned on polymer  2 did not show 
any pattern contrast (data not shown). This again dem-
onstrates the orthogonality of the alkyne–azide chem-
istry and the aldehyde–hydrazide chemistry we use. The 
alkyne–azide chemistry is chosen for immobilization of 
a second biomolecule, here a cyclic RGD (cRGD) peptide, 
because of its high effi ciency and natural orthogonality to 
other commonly used bioconjugation chemistries. [ 13 ] 
 4. Conclusions 
 We successfully prepared a new CVD copolymer for orthog-
onal co-immobilization of heparin-binding growth factors 
with an adhesion peptide. To establish a generic growth 
factor immobilization scheme, the CVD co-polymer was 
modifi ed to allow for immobilization of heparin onto the 
surface. The presence of heparin leads to non-covalent 
binding of heparin-binding growth factors and can poten-
tially enhance the bioactivity of the growth factor. In 
parallel, an adhesion peptide is also immobilized to the 
surface using orthogonal bioconjugation schemes. Due to 
the substrate-independent nature of the CVD polymeriza-
tion process, this novel procedure is rather generic and can 
be a widely applied as a surface engineering platform for a 
broad range of biomedical applications. Further biological 
studies are under way to identify the quantitative informa-
tion about the co-immobilization ratios that will be associ-
ated with the highest biological activity in cell culture. We 
note that the biomolecules that can be orthogonally immo-
bilized via the herein reported procedure are not limited 
to adhesion peptides and growth factors. While other bio-
molecules such as enzymes, antibodies, or polysaccharides 
are also compatible with this approach, this strategy is not 
suitable for co-immobilization of multiple heparin-binding 
growth factors. In this case, more traditional orthogonal 
immobilization strategies will need to be employed. [ 13 ] Macromol. Rapid Commu
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